Trisalus Life Sciences, Inc. ( (TLSI) ) has released its Q3 earnings. Here is a breakdown of the information Trisalus Life Sciences, Inc. presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
TriSalus Life Sciences, Inc. is an oncology-focused medical technology company that integrates innovative delivery technology with standard-of-care therapies to improve outcomes for patients with solid tumors. The company is known for its proprietary Pressure-Enabled Drug Delivery (PEDD) technology and investigational immunotherapeutic, nelitolimod.
In its third-quarter 2025 earnings report, TriSalus Life Sciences reported a significant increase in revenue, reaching $11.6 million, which marks a 57% year-over-year growth. This growth is primarily attributed to the increased adoption of their TriNav product suite for liver embolization. The company also reaffirmed its full-year revenue growth guidance of at least 50%.
Key financial highlights include a gross margin of 84% and a reduction in quarterly cash burn by approximately 50%. The company also simplified its capital structure through a successful exchange offering of Series A Preferred stock. Additionally, TriSalus is advancing its clinical programs, including the completion of three PERIO clinical phase 1 dose escalation studies and the initiation of a clinical trial for genicular artery embolization as a potential treatment for knee osteoarthritis.
Despite the positive revenue growth, TriSalus reported a net loss attributable to common stockholders of $41.3 million for the third quarter, primarily due to the conversion of preferred stock to common stock. The company ended the quarter with $22.7 million in cash and cash equivalents, providing a sufficient runway to reach positive adjusted EBITDA.
Looking ahead, TriSalus Life Sciences remains committed to expanding the application of its PEDD technology and improving patient outcomes. The company is focused on building a data-driven case for its technology and exploring partnership opportunities for the development of nelitolimod, reflecting a strategic shift in its business operations.